Treatment
Cell clinical trials
We’re tracking 5,550 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT03523975RecruitingPhase 1/Phase 2
Testing venetoclax, lenalidomide, and rituximab for new mantle cell lymphoma
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
Duarte, CaliforniaAges 18 years+ - NCT03435796RecruitingPhase 2/Phase 3
Follow-up for people treated with gene-modified T cells
This study is a long-term check-in for people who previously received gene-modified T-cell infusions in a related Celgene/Juno/BMS trial. It helps researchers track safety and long-term effects over time.
Birmingham, AlabamaAges Any age - NCT03391778Enrolling by invitationPhase 1
Long-term follow-up for cell therapy participants
This study checks how people do over time after receiving an “adoptive cell therapy” treatment. It helps researchers understand long-term safety and outcomes after prior participation in related studies.
Atlanta, GeorgiaAges Any age - NCT03353584Recruiting
Virtual reality for pain relief during sickle cell pain crises
This trial tests whether a virtual reality (VR) experience can help reduce pain during a sickle cell “vaso-occlusive crisis,” which is an episode of sudden, severe pain. It’s offered alongside the care team’s usual pain management to see if VR makes pain feel better.
Memphis, TennesseeAges 6–25 - NCT03425526RecruitingPhase 1
Donor T-cell treatment for adenovirus illness in immune-weakened people
This early-phase study tests donor immune cells (T cells) to treat people who have adenovirus infection or adenovirus-related disease but have a weakened immune system. It may help your body fight the virus, especially in cases where other treatments may not be enough.
Houston, TexasAges Any age - NCT03295981RecruitingPhase 3
Bisphosphonate treatment to prevent giant cell tumor return
This study looks at whether taking a bone-strengthening medicine called a bisphosphonate after surgery can lower the chance that a giant cell tumor in a leg or arm comes back. It may help prevent recurrence after removing the tumor from the bone.
Los Angeles, CaliforniaAges 18 years+ - NCT03223610RecruitingPhase 1/Phase 2
ViPOR treatment for relapsed or hard-to-treat lymphoma
This Phase 1/2 trial tests a combination of several medicines (venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid) for lymphoma that has come back or did not respond. It aims to shrink tumors safely and improve responses in people with specific types of B-cell lymphoma.
Bethesda, MarylandAges 18–120 - NCT03226704Enrolling by invitation
Leukapheresis to prepare CAR cell therapy
This trial collects white blood cells through a procedure called leukapheresis to help make CAR or other adoptive cell therapies. It’s for people with certain cancers who are not in remission (or are at high risk of relapse) and can meet health and lab requirements.
Bethesda, MarylandAges 3–65 - NCT03219359RecruitingPhase 2
Stem cell transplant using your own cells for Crohn’s flare
This Phase 2 study tests whether a transplant using your own stem cells can calm active Crohn’s disease that hasn’t improved with standard medicines. It may help some people with ongoing inflammation and symptoms after multiple Crohn’s treatments.
New York, New YorkAges 18 years+ - NCT03113643RecruitingPhase 1
SL-401 with standard drugs for hard-to-treat blood cancers
This Phase 1 study tests SL-401, given with azacitidine and sometimes venetoclax, to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN). It aims to find a safe dose and see whether the combination can improve blood cancer control.
Duarte, CaliforniaAges 18 years+ - NCT03136146RecruitingPhase 2
Chemo for return or non-responsive blood cancers
This Phase 2 study tests a combination chemotherapy plan for certain leukemia and lymphoma types that have come back or did not respond. It may help shrink or control disease when standard treatment is no longer working.
Houston, TexasAges 15 years+ - NCT03210935Recruiting
National registry for rare skin cancer diagnoses
This trial is a French national database that collects information from people with certain rare skin cancers. It may help researchers better understand these cancers and improve future care, using real-world patient data.
Dijon, DijonAges Any age - NCT03280394Recruiting
Liquid blood test for mature B-cell tumors
This study looks at how a “liquid biopsy,” a test done on blood, may help in people with mature B-cell tumors. It mainly checks whether you can take part and complete the planned study procedures.
Bellinzona, Canton TicinoAges 18 years+ - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT02795052Recruiting
Stem cell treatment trial for nerve injury
This study tests whether bone-marrow stem cells can improve nerve function in people with nerve damage that usually doesn’t recover with current care. It also checks whether the treatment is safe and whether people can be followed over time with repeated nerve exams.
Westport, ConnecticutAges 18 years+ - NCT03011541Recruiting
Stem cell treatment for damaged retina or optic nerve
This study looks at stem-cell treatment to help vision in adults whose retina or optic nerve damage is not expected to improve on its own. You may be a candidate if your eye exam shows documented, stable or slowly changing damage and you can safely complete follow-up eye visits.
Westport, ConnecticutAges 18 years+ - NCT03000244Recruiting
Long-term follow-up after stem cell or gene therapy
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
Bethesda, MarylandAges 4–120 - NCT02682667Recruiting
Providing blood samples for cancer immunotherapy research
This study collects and stores blood/tissue samples (called biospecimens) to support immunotherapy research at the cancer center. If you may qualify, your samples help researchers test new immune-based cancer treatments.
Bethesda, MarylandAges 18–120 - NCT02688894Recruiting
Molecular testing for relapsed small cell lung cancer
This study uses tumor tissue to look for molecular (biologic) changes after your small cell lung cancer comes back. It may help doctors choose the most appropriate next treatment based on what the cancer’s biology shows.
IncheonAges 20 years+ - NCT02824471Recruiting
Testing a chip technology for sickle cell samples
This trial tests a “biochip” device using samples from people with sickle cell disease. If it works, it may help doctors study sickle cell biology more accurately using patient samples.
Cleveland, OhioAges 12 years+ - NCT02743832Recruiting
Personalized surgery planning for early mouth cancer
This study helps doctors plan surgery more individually for early-stage oral (mouth) squamous cell carcinoma. It focuses on using tumor features found during evaluation to guide surgical decisions, aiming to improve treatment accuracy.
Guangzhou, GuangdongAges 20–70 - NCT02917083RecruitingPhase 1
CD30 CAR T cell treatment for hard-to-treat lymphomas
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
Houston, TexasAges 12–75 - NCT02772367Recruiting
Make heart muscle cells from blood or skin in breast cancer
This study grows heart muscle cells from your blood or skin to better understand why some people develop heart problems from HER2 cancer treatments. You may be helping researchers learn how to predict and prevent treatment-related heart damage.
New York, New YorkAges 18 years+ - NCT02675959RecruitingPhase 2
Transplant with defibrotide for sickle cell disease
This trial tests a stem cell transplant from a half-matched donor using a strong conditioning regimen and a drug called defibrotide to protect organs. It aims to cure sickle cell disease in patients who have had serious complications like stroke, chest syndrome, or frequent pain episodes.
Los Angeles, CaliforniaAges 6 months–21 years
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,550 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.